Illumina, Inc.
ILMN · Healthcare
$207.13
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
The Market Just Told You Which Layer Of AI Biology It Is Paying For
Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics shares have gained 7.1% since its Q2 2026 earnings report, outperforming the S&P 500. The company beat earnings estimates with a narrower loss of $0.94 per share versus $1.10 expected, and revenues of $10.2 million exceeded the $7 million consensus. Vertex's Casgevy sales reached $76 million with 151% year-over-year growth. CRISPR has controlled costs across R&D, G&A, and collaboration expenses. Analysts have revised estimates upward by 10.46%, though the stock maintains a Zacks Rank #3 (Hold) with an overall VGM Score of F.
Is This the Right Time to Add PBH Stock to Your Portfolio?
Prestige Consumer Healthcare (PBH) is a Zacks Rank #2 (Buy) stock benefiting from strategic acquisitions of Breathe Right and LaCorium Health, expected to add nearly 20% to its revenue base and lift fiscal 2027 guidance to $1.29-$1.315 billion. The company's e-commerce channel has grown to 18% of net sales with double-digit growth momentum. However, elevated debt levels ($2.0 billion net debt) and foreign exchange exposure pose risks to profitability.
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector
Thermo Fisher Scientific unveiled the EMPAD G2 detector, enabling faster 4D STEM materials analysis at 10,000 frames per second with atomic-scale characterization. The detector integrates with Velox software for simplified analysis. The global 4D STEM market is projected to grow from $68 million in 2024 to $110 million by 2031 at a 6.6% CAGR, supporting TMO's growth prospects in analytical instruments.
Neogen Surges 102.8% in a Year: What's Driving the Rally?
Neogen Corporation (NEOG) has demonstrated strong performance with shares rising 102.8% over the past year, outperforming the industry. The company's Food Safety division achieved its highest quarterly core growth rate since fiscal 2023 at 5.8%, while planning a 50% increase in fiscal 2027 R&D spending focused on innovation and pathogen detection. However, the company faces headwinds from foreign currency exposure affecting 51.2% of revenues and intense competition from larger corporations.